Poorer oxygen uptake and transport may underlie skeletal muscle differences that affect exercise tolerance in children and adolescents with cystic fibrosis (CF) relative to healthy peers, a recent study suggests. The study, “Tissue oxygenation in peripheral muscles and functional capacity in cystic fibrosis: A cross‐sectional study,”…
cystic fibrosis
The European Commission (EC) approved Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in people 12 and older who have either two F508del mutations or one F508del mutation and one minimal function mutation in the CFTR gene. The decision follows a positive opinion,…
Note: This story was updated Aug. 25, 2020, to clarify that, according to NuvoAir, the regulatory entity in question is the European Medical Device Directive. The NuvoAir Home platform, NuvoAir’s respiratory support system for patients with lung diseases such as cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF),…
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to KB407, Krystal Biotech’s potential inhaled gene therapy for the treatment of cystic fibrosis (CF). “We are pleased to receive Orphan Drug Designation for KB407 to treat cystic fibrosis as…
Enterprise Therapeutics announced that dosing has begun in a Phase 1 clinical trial testing ETD002, a potential inhaled treatment for cystic fibrosis (CF). The study (NCT04488705) will assess the safety and tolerability of EDT002 in ascending single and multiple doses in healthy people as compared with a matching placebo.
The nonprofit Claire’s Place Foundation has launched a pilot program to help 15 adults with cystic fibrosis (CF) or caregivers of patients acquire flexible employment, enabling them to continue working while dealing with the disease’s daily needs. The Work Proudly Program aids people in choosing careers and gaining the…
AzurRx BioPharma has enrolled the first three patients in its Phase 2b trial investigating MS1819 as a treatment for exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. The trial, dubbed OPTION 2 (NCT04375878), aims to enroll 30 CF patients ages 18 and older. Top-line…
A Phase 1/2 clinical trial assessing Arrowhead Pharmaceuticals‘ investigational inhaled therapy, ARO-ENaC, for the treatment of cystic fibrosis (CF), has dosed its first participants, the company announced. The AROENaC1001 trial (NCT04375514) is designed to investigate ARO-ENaC in 24 healthy volunteers and 30 CF patients, and is…
Cystic Fibrosis Ireland has set aside up to €120,000 ($141,150) to provide personal protective equipment (PPE) to people with cystic fibrosis (CF) in the Republic of Ireland. Those interested may apply for individual grants of €100 per applicant through Aug. 22. Applications to the PPE grant should be…
New research unveils why the bacteria Pseudomonas aeruginosa cause sustained infections in younger cystic fibrosis (CF) patients, while the bacteria Burkholderia cepacia complex infects patients as teenagers and adults. The findings show that P. aeruginosa loses the ability to use its toxic weaponry after it adapts to the lungs, allowing Burkholderia cepacia complex to…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.